Q32 Bio Inc.
QTTB
$15.15
-$0.22-1.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 32.35% | -2.93% | |||
| Gross Profit | -32.35% | -106.38% | |||
| SG&A Expenses | 7.88% | -0.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.08% | -1.73% | |||
| Operating Income | -18.08% | -116.83% | |||
| Income Before Tax | -17.57% | -113.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -17.57% | -113.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -17.57% | -113.18% | |||
| EBIT | -18.08% | -116.83% | |||
| EBITDA | -18.36% | -116.60% | |||
| EPS Basic | 18.53% | -111.75% | |||
| Normalized Basic EPS | 19.89% | -114.72% | |||
| EPS Diluted | 18.52% | -111.77% | |||
| Normalized Diluted EPS | 19.89% | -114.76% | |||
| Average Basic Shares Outstanding | 44.32% | 12.20% | |||
| Average Diluted Shares Outstanding | 44.32% | 11.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||